After a rigorous investigation procedure by the Food and Drug Administration, FibriCheck is now FDA-cleared (K232804). This is an important milestone which supports our further development in the U.S. market. The FDA-clearance allows us to improve current U.S. care pathways…
In recent years the surge of AI technology has allowed for a variety of healthcare applications to be developed. These applications are a great way to empower and motivate users to track their own health, and are a valuable addition…
FibriCheck has partnered with Roche Diagnostics, Hong Kong’s leading digital health platform DrGo and the Hong Kong Society for Rehabilitation (HKSR) for a large-scale targeted AF detection campaign among Hong Kong’s population. Following a successful FibriCheck integration, Hongkongers are now…
FibriCheck is proud to announce that in addition to being among the first to go through Orcha’s rigorous assessment process, we are leading the charge in digital health standards compliance, as evidenced by the 100% rating received by the leading…
We started 2021 off strong with a new investment round. The newly invested 9 million euros allowed us to further accelerate the growth of both our business units. While keeping one eye on international growth, the FibriCheck app is also…
FibriCheck, the app capable of detecting heart rhythm disorders like atrial fibrillation, is now available in Australia for use with compatible smartphones (both iPhone and Android) as well as selected smartwatches. This means that the more than 500.000 Australians at…
Brussels, October 8th 2018 – A new scoop for Digital Health with the FDA clearance of FibriCheck. The American watchdog, FDA, has a strict regulatory process for medical applications before they can enter the American market. FibriCheck, a Belgian medical…